Clinical Trial Update: Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports safety and efficacy data for LEE011 and LGX818 in patients with BRAF-mutant melanoma (Phase 1/2). The study was terminated an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• LEE011 (ribociclib)
• LGX818 (encorafenib)

Snippet

Sponsor: Array BioPharma | Conditions: Locally Advanced Metastatic BRAF Mutant Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-09-13